Specific binding members for TGFβ1
US7151169B2 · kind B2 · utility
40Cited by
24References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2002 |
| Grant date | Dec 19, 2006 |
| Priority date | — |
| Expiry date | Feb 26, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGFβ1 and are useful in treating conditions associated with excess TGFβ1 activity, such as fibrosis, immune responses and tumor progression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.